ATE289593T1 - Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden - Google Patents

Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden

Info

Publication number
ATE289593T1
ATE289593T1 AT00930341T AT00930341T ATE289593T1 AT E289593 T1 ATE289593 T1 AT E289593T1 AT 00930341 T AT00930341 T AT 00930341T AT 00930341 T AT00930341 T AT 00930341T AT E289593 T1 ATE289593 T1 AT E289593T1
Authority
AT
Austria
Prior art keywords
compounds
carboxamide
quinoline
oxo
substituted
Prior art date
Application number
AT00930341T
Other languages
English (en)
Inventor
Pamela A Albaugh
Kevin S Currie
Daniel Rosewater
Goulin Cai
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ATE289593T1 publication Critical patent/ATE289593T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00930341T 1999-05-06 2000-05-05 Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden ATE289593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294099P 1999-05-06 1999-05-06
PCT/US2000/012096 WO2000068202A1 (en) 1999-05-06 2000-05-05 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
ATE289593T1 true ATE289593T1 (de) 2005-03-15

Family

ID=22456276

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00930341T ATE289593T1 (de) 1999-05-06 2000-05-05 Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden

Country Status (11)

Country Link
US (1) US6413956B1 (de)
EP (1) EP1177177B1 (de)
JP (1) JP2002544197A (de)
AT (1) ATE289593T1 (de)
AU (1) AU4818000A (de)
BR (1) BR0010308A (de)
CA (1) CA2371472A1 (de)
DE (1) DE60018274T2 (de)
ES (1) ES2235883T3 (de)
MX (1) MXPA01011173A (de)
WO (1) WO2000068202A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
WO2001098266A2 (en) * 2000-06-20 2001-12-27 Wayne State University N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
BR0209932A (pt) 2001-05-22 2004-10-13 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
EP1935885A3 (de) * 2001-05-22 2008-10-15 Neurogen Corporation Rezeptorliganden des melaninkonzentrierenden Hormons: substituierte 1-Benzyl-4-Aryl-Piperazinanaloga
ATE417613T1 (de) * 2002-05-14 2009-01-15 Univ California Substituierte chinoloncarbonsäuren, ihre derivate,wirkungsort und anwendungen
AU2003243637A1 (en) * 2002-06-19 2004-01-06 Schering Corporation Cannabinoid receptor agonists
JP2006517958A (ja) * 2003-02-19 2006-08-03 ニューロジェン・コーポレイション アリール酸ピリミジニルメチルアミド、ピリダジニルメチルアミドおよび関連化合物
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
EP2502913A3 (de) * 2004-06-24 2013-11-27 Vertex Pharmaceuticals Incorporated Modulatoren von Transportern der ATP-bindenden Kassette
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RU2378256C2 (ru) * 2004-11-01 2010-01-10 Ф. Хоффманн-Ля Рош Аг Хинолин в качестве аллостерического энхансера рецепторов гамк-в
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
CN101443314B (zh) * 2006-03-13 2014-04-09 杏林制药株式会社 作为gsk-3抑制剂的氨基喹诺酮类
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2008046135A1 (en) * 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
AU2009215033A1 (en) * 2008-02-15 2009-08-20 Merck Sharp & Dohme Corp. Fused pyridone M1 receptor positive allosteric modulators
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
RU2011137419A (ru) * 2009-02-11 2013-03-20 Суновион Фармасьютикалз Инк. Обратные агонисты и антагонисты гистамина н3 и способы их применения
EP2821400B1 (de) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Verfahren zur Herstellung von CFTR-Regulatoren
JP2013504580A (ja) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
WO2012151640A1 (en) 2011-05-12 2012-11-15 Bionomics Limited Methods for preparing naphthyridines
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
DK2825542T3 (en) 2012-03-16 2017-01-09 Vitae Pharmaceuticals Inc LIVER-X-receptor modulators
CA2866218C (en) 2012-03-16 2020-06-09 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
CN104230853B (zh) * 2014-08-18 2016-04-13 湖南华腾制药有限公司 一种(对甲苯基)甲胺-n-乙基吗啉盐酸盐的制备方法
EP3194367B1 (de) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Zur behandlung von übergewicht und diabetes geeignete tetrahydroisochinolin derivate und pharmazeutische zusammensetzungen
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN105330602B (zh) * 2015-12-07 2018-02-09 江南大学 一种癸氧喹酯类似物及其应用
KR101882790B1 (ko) 2017-04-10 2018-08-24 한양대학교 산학협력단 Dusp1 저해제를 함유하는 약제학적 조성물
TW202342433A (zh) * 2022-02-25 2023-11-01 比利時魯汶大學 用於抑制ｙａｐ／ｔａｚ—ｔｅａｄ之二氫喹唑啉酮及相關類似物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190796B (en) * 1981-06-12 1986-11-28 Roussel Uclaf,Fr Process for producing n-dihydrothiazolyl-3-quinoline-carboxamide derivatives
FR2509728A1 (fr) * 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US4777252A (en) * 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative
DE69329654T2 (de) * 1992-08-19 2001-03-15 Mcneilab Inc 3-oxo-pyrido [1,2-a] benzimidazol-4-carboxyl und 4-oxo-azepino [1,2-a] benzimidazol-5-carboxyl derivate geeignet für die behandlung von zentralnervensystemerkrankungen
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
AU753800B2 (en) * 1997-08-25 2002-10-31 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
CA2309882A1 (en) * 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents

Also Published As

Publication number Publication date
JP2002544197A (ja) 2002-12-24
MXPA01011173A (es) 2002-04-24
WO2000068202A1 (en) 2000-11-16
EP1177177A1 (de) 2002-02-06
BR0010308A (pt) 2002-01-08
DE60018274D1 (de) 2005-03-31
DE60018274T2 (de) 2005-08-04
AU4818000A (en) 2000-11-21
CA2371472A1 (en) 2000-11-16
EP1177177B1 (de) 2005-02-23
US6413956B1 (en) 2002-07-02
ES2235883T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
DE60018274D1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
ATE307127T1 (de) 2,4-substituierte pyridinderivate
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
WO2000077008A3 (en) Heteroaryl substituted piperidines as gaba brain receptor lingands
FR2732017B1 (fr) Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK0555391T3 (da) Visse imidazoquinoxaliner; en ny klasse GABA-receptorligander i hjernen
AP2002002420A0 (en) Fused pyrrolecarboxamides: gaba brain receptor ligands.
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon
BR0009539A (pt) composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
LV12539A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
BR9908321A (pt) Composto
BR0113697A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, embalagem e métodos para, para alterar a atividade transdutora de sinal dos receptores de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, para demonstrar a presença dos receptores de gabaa em células ou amostras de tecido e para preparar um composto
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
BR0307504A (pt) Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal
BRPI0514380A (pt) amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
DE69926378D1 (de) Oxo-pyridoimidazol-carboxamide: gaba-rezeptor-liganden im gehirn
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.
DK1192161T3 (da) Chromeno[4,3,2-de]isoquinoliner som kraftige dopaminreceptorligander
TNSN00178A1 (en) Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands
CA2249562A1 (en) Certain fused pyrrolecarboxamides as gaba brain receptor ligands

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties